The FDA issued over 100 warning letters to telehealth companies, including Hims & Hers, for promoting unapproved, compounded versions of prescription weight-loss drugs like Wegovy and Ozempic. The letters, part of a broader crackdown on pharmaceutical advertising, allege false and misleading claims that these compounded medications are equivalent to FDA-approved drugs. Hims & Hers stated they will cooperate with the FDA. This action marks the FDA's first direct attempt to regulate online platforms promoting such products, following a recent White House directive to ensure truthful pharmaceutical advertising.

Prepared by Olivia Bennett and reviewed by editorial team.